Deepak Cyril Dsouza, MBBS, MD < Yale ...

Dr. Deepak C. D'Souza, M.D.

Claim this profile

Biological Studies Unit, VA Connecticut Healthcare System

Studies Substance Abuse
Studies Cannabis
8 reported clinical trials
11 drugs studied

Affiliated Hospitals

Image of trial facility.
Biological Studies Unit, VA Connecticut Healthcare System
Image of trial facility.
Connecticut Mental Health Center

Clinical Trials Deepak C. D'Souza, M.D. is currently running

Image of trial facility.

THC

for HIV

In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.
Recruiting1 award Phase 16 criteria
Image of trial facility.

PET Imaging

for Various Conditions

The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, \[11C\]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available. Those in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia.
Recruiting1 award N/A9 criteria

More about Deepak C. D'Souza, M.D.

Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Deepak C. D'Souza, M.D. has experience with
  • Active Ethanol
  • Placebo
  • Iclepertin
  • [11-C]OMAR
  • PF-04457845
  • Dimethyltryptamine (DMT)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Deepak C. D'Souza, M.D. specialize in?
Is Deepak C. D'Souza, M.D. currently recruiting for clinical trials?
Are there any treatments that Deepak C. D'Souza, M.D. has studied deeply?
What is the best way to schedule an appointment with Deepak C. D'Souza, M.D.?
What is the office address of Deepak C. D'Souza, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security